Press release
Overactive Bladder Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, by DelveInsight | Astellas Pharma Inc., Laborie, Hisamitsu Pharma, Inc., Medtronic, Pfizer Inc, Teva Pharma
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Overactive Bladder pipeline constitutes 15+ key companies continuously working towards developing 15+ Overactive Bladder treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Overactive Bladder Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Overactive Bladder Market.
The Overactive Bladder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Overactive Bladder Pipeline Report:
https://www.delveinsight.com/sample-request/overactive-bladder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Overactive Bladder treatment therapies with a considerable amount of success over the years.
• Overactive Bladder companies working in the treatment market are Aardvark Therapeutics, Exxel Pharma, Hugel, Imbrium Therapeutics, Taiho Pharmaceutical, Sumitovant Biopharma, Dong-A ST, and others, are developing therapies for the Overactive Bladder treatment
• Emerging Overactive Bladder therapies in the different phases of clinical trials are- ARD-380, URB937, Botulax, IMB-115, TAC-302, URO-902, DA-8010, and others are expected to have a significant impact on the Overactive Bladder market in the coming years.
• In April 2024, SpineX has completed patient enrollment for its CONTINENCE clinical trial (NCT05301335), which evaluates the Scone neuromodulation device for treating neurogenic bladder, often associated with conditions like multiple sclerosis (MS), stroke, or spinal cord injury. Conducted at multiple sites across the U.S., Canada, and India, the study targets adults experiencing overactive bladder symptoms due to these neurological conditions. Researchers at SpineX are optimistic that participants in the trial will experience notable enhancements in self-reported symptoms linked to neurogenic bladder.
• In November 2023, Avation Medical has disclosed encouraging outcomes from the multi-center trial of Vivally, its medical device aimed at addressing overactive bladder (OAB) syndrome. The FREEOAB multi-center study involved 96 OAB patients. Findings indicated notable decreases in daily void, incontinence, and urgency episodes at the 12-week mark, leading to an improved quality of life. Furthermore, these favorable effects endured over the long term, with ongoing enhancements in diary parameters noted at the 12-month follow-up.
Overactive Bladder Overview
Overactive bladder (OAB) is a urinary condition characterized by a frequent and sudden urge to urinate that may be difficult to control. People with OAB often experience urinary urgency, which can lead to involuntary leakage of urine (urge incontinence). This condition can significantly impact daily life and quality of life.
Get a Free Sample PDF Report to know more about Overactive Bladder Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/overactive-bladder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Overactive Bladder Drugs Under Different Phases of Clinical Development Include:
• ARD-380: Aardvark Therapeutics
• URB937: Exxel Pharma
• Botulax: Hugel
• IMB-115: Imbrium Therapeutics
• TAC-302: Taiho Pharmaceutical
• URO-902: Sumitovant Biopharma
• DA-8010: Dong-A ST
Overactive Bladder Route of Administration
Overactive Bladder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
Overactive Bladder Molecule Type
Overactive Bladder Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule
Overactive Bladder Pipeline Therapeutics Assessment
• Overactive Bladder Assessment by Product Type
• Overactive Bladder By Stage and Product Type
• Overactive Bladder Assessment by Route of Administration
• Overactive Bladder By Stage and Route of Administration
• Overactive Bladder Assessment by Molecule Type
• Overactive Bladder by Stage and Molecule Type
DelveInsight's Overactive Bladder Report covers around 15+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Overactive Bladder product details are provided in the report. Download the Overactive Bladder pipeline report to learn more about the emerging Overactive Bladder therapies
https://www.delveinsight.com/sample-request/overactive-bladder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Overactive Bladder Therapeutics Market include:
Key companies developing therapies for Overactive Bladder are - Astellas Pharma Inc., Laborie, Endo International PLC, Hisamitsu Pharma, Inc., Medtronic, Pfizer Inc, Teva Pharma, AbbVie Inc, Allergan, Macleods Pharmaceuticals Ltd, Urovant Sciences, Uro Medical, and others.
Overactive Bladder Pipeline Analysis:
The Overactive Bladder pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Overactive Bladder with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Overactive Bladder Treatment.
• Overactive Bladder key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Overactive Bladder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Overactive Bladder market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Overactive Bladder drugs and therapies
https://www.delveinsight.com/sample-request/overactive-bladder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Overactive Bladder Pipeline Market Drivers
• Prevalence of urinary incontinence, approval of generics, growth in the number of product launches are some of the important factors that are fueling the Overactive Bladder Market.
Overactive Bladder Pipeline Market Barriers
• However, lack of diagnosis and information about OAB, side effects associated with the current treatment options and other factors are creating obstacles in the Overactive Bladder Market growth.
Scope of Overactive Bladder Pipeline Drug Insight
• Coverage: Global
• Key Overactive Bladder Companies: Aardvark Therapeutics, Exxel Pharma, Hugel, Imbrium Therapeutics, Taiho Pharmaceutical, Sumitovant Biopharma, Dong-A ST, and others
• Key Overactive Bladder Therapies: ARD-380, URB937, Botulax, IMB-115, TAC-302, URO-902, DA-8010, and others
• Overactive Bladder Therapeutic Assessment: Overactive Bladder current marketed and Overactive Bladder emerging therapies
• Overactive Bladder Market Dynamics: Overactive Bladder market drivers and Overactive Bladder market barriers
Request for Sample PDF Report for Overactive Bladder Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/overactive-bladder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Overactive Bladder Report Introduction
2. Overactive Bladder Executive Summary
3. Overactive Bladder Overview
4. Overactive Bladder- Analytical Perspective In-depth Commercial Assessment
5. Overactive Bladder Pipeline Therapeutics
6. Overactive Bladder Late Stage Products (Phase II/III)
7. Overactive Bladder Mid Stage Products (Phase II)
8. Overactive Bladder Early Stage Products (Phase I)
9. Overactive Bladder Preclinical Stage Products
10. Overactive Bladder Therapeutics Assessment
11. Overactive Bladder Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Overactive Bladder Key Companies
14. Overactive Bladder Key Products
15. Overactive Bladder Unmet Needs
16 . Overactive Bladder Market Drivers and Barriers
17. Overactive Bladder Future Perspectives and Conclusion
18. Overactive Bladder Analyst Views
19. Appendix
20. About DelveInsight
Related Reports:
Overactive Bladder Market https://www.delveinsight.com/report-store/overactive-bladder-oab-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Overactive Bladder Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Overactive Bladder Epidemiology https://www.delveinsight.com/report-store/overactive-bladder-oab-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Overactive Bladder Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports:
H3n2 Infection Market
https://www.delveinsight.com/report-store/h3n2-infection-market
DelveInsight's "H3N2 Infection Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the H3N2 Infection, historical and forecasted epidemiology as well as the H3N2 Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Herpes Simplex Virus Market
https://www.delveinsight.com/report-store/herpes-simplex-market
DelveInsight's "Herpes Simplex Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Herpes Simplex, historical and forecasted epidemiology as well as the Herpes Simplex market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Hypercoagulability Market
https://www.delveinsight.com/report-store/hypercoagulability-market
DelveInsight's "Hypercoagulability Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hypercoagulability, historical and forecasted epidemiology as well as the Hypercoagulability market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Liver Angiosarcoma Market
https://www.delveinsight.com/report-store/liver-angiosarcoma-market
DelveInsight's "Liver Angiosarcoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Liver Angiosarcoma, historical and forecasted epidemiology as well as the Liver Angiosarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Point Of Care Glucose Testing Market
https://www.delveinsight.com/report-store/point-of-care-glucose-testing-market
DelveInsight's 'Point of Care Glucose Testing Market Insight, Competitive Landscape and Market Forecast, 2030' report delivers an in-depth understanding of Point of Care Glucose Testing and the historical and forecasted Point of Care Glucose Testing market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Resorbable Vascular Scaffold Market
https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market
DelveInsight's 'Resorbable Vascular Scaffolds - Market Insight, Competitive Landscape, and Market Forecast - 2030' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
"Overactive Bladder Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Overactive Bladder Market.
The Overactive Bladder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Overactive Bladder Pipeline Report:
https://www.delveinsight.com/sample-request/overactive-bladder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Overactive Bladder treatment therapies with a considerable amount of success over the years.
• Overactive Bladder companies working in the treatment market are Aardvark Therapeutics, Exxel Pharma, Hugel, Imbrium Therapeutics, Taiho Pharmaceutical, Sumitovant Biopharma, Dong-A ST, and others, are developing therapies for the Overactive Bladder treatment
• Emerging Overactive Bladder therapies in the different phases of clinical trials are- ARD-380, URB937, Botulax, IMB-115, TAC-302, URO-902, DA-8010, and others are expected to have a significant impact on the Overactive Bladder market in the coming years.
• In April 2024, SpineX has completed patient enrollment for its CONTINENCE clinical trial (NCT05301335), which evaluates the Scone neuromodulation device for treating neurogenic bladder, often associated with conditions like multiple sclerosis (MS), stroke, or spinal cord injury. Conducted at multiple sites across the U.S., Canada, and India, the study targets adults experiencing overactive bladder symptoms due to these neurological conditions. Researchers at SpineX are optimistic that participants in the trial will experience notable enhancements in self-reported symptoms linked to neurogenic bladder.
• In November 2023, Avation Medical has disclosed encouraging outcomes from the multi-center trial of Vivally, its medical device aimed at addressing overactive bladder (OAB) syndrome. The FREEOAB multi-center study involved 96 OAB patients. Findings indicated notable decreases in daily void, incontinence, and urgency episodes at the 12-week mark, leading to an improved quality of life. Furthermore, these favorable effects endured over the long term, with ongoing enhancements in diary parameters noted at the 12-month follow-up.
Overactive Bladder Overview
Overactive bladder (OAB) is a urinary condition characterized by a frequent and sudden urge to urinate that may be difficult to control. People with OAB often experience urinary urgency, which can lead to involuntary leakage of urine (urge incontinence). This condition can significantly impact daily life and quality of life.
Get a Free Sample PDF Report to know more about Overactive Bladder Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/overactive-bladder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Overactive Bladder Drugs Under Different Phases of Clinical Development Include:
• ARD-380: Aardvark Therapeutics
• URB937: Exxel Pharma
• Botulax: Hugel
• IMB-115: Imbrium Therapeutics
• TAC-302: Taiho Pharmaceutical
• URO-902: Sumitovant Biopharma
• DA-8010: Dong-A ST
Overactive Bladder Route of Administration
Overactive Bladder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
Overactive Bladder Molecule Type
Overactive Bladder Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule
Overactive Bladder Pipeline Therapeutics Assessment
• Overactive Bladder Assessment by Product Type
• Overactive Bladder By Stage and Product Type
• Overactive Bladder Assessment by Route of Administration
• Overactive Bladder By Stage and Route of Administration
• Overactive Bladder Assessment by Molecule Type
• Overactive Bladder by Stage and Molecule Type
DelveInsight's Overactive Bladder Report covers around 15+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Overactive Bladder product details are provided in the report. Download the Overactive Bladder pipeline report to learn more about the emerging Overactive Bladder therapies
https://www.delveinsight.com/sample-request/overactive-bladder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Overactive Bladder Therapeutics Market include:
Key companies developing therapies for Overactive Bladder are - Astellas Pharma Inc., Laborie, Endo International PLC, Hisamitsu Pharma, Inc., Medtronic, Pfizer Inc, Teva Pharma, AbbVie Inc, Allergan, Macleods Pharmaceuticals Ltd, Urovant Sciences, Uro Medical, and others.
Overactive Bladder Pipeline Analysis:
The Overactive Bladder pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Overactive Bladder with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Overactive Bladder Treatment.
• Overactive Bladder key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Overactive Bladder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Overactive Bladder market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Overactive Bladder drugs and therapies
https://www.delveinsight.com/sample-request/overactive-bladder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Overactive Bladder Pipeline Market Drivers
• Prevalence of urinary incontinence, approval of generics, growth in the number of product launches are some of the important factors that are fueling the Overactive Bladder Market.
Overactive Bladder Pipeline Market Barriers
• However, lack of diagnosis and information about OAB, side effects associated with the current treatment options and other factors are creating obstacles in the Overactive Bladder Market growth.
Scope of Overactive Bladder Pipeline Drug Insight
• Coverage: Global
• Key Overactive Bladder Companies: Aardvark Therapeutics, Exxel Pharma, Hugel, Imbrium Therapeutics, Taiho Pharmaceutical, Sumitovant Biopharma, Dong-A ST, and others
• Key Overactive Bladder Therapies: ARD-380, URB937, Botulax, IMB-115, TAC-302, URO-902, DA-8010, and others
• Overactive Bladder Therapeutic Assessment: Overactive Bladder current marketed and Overactive Bladder emerging therapies
• Overactive Bladder Market Dynamics: Overactive Bladder market drivers and Overactive Bladder market barriers
Request for Sample PDF Report for Overactive Bladder Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/overactive-bladder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Overactive Bladder Report Introduction
2. Overactive Bladder Executive Summary
3. Overactive Bladder Overview
4. Overactive Bladder- Analytical Perspective In-depth Commercial Assessment
5. Overactive Bladder Pipeline Therapeutics
6. Overactive Bladder Late Stage Products (Phase II/III)
7. Overactive Bladder Mid Stage Products (Phase II)
8. Overactive Bladder Early Stage Products (Phase I)
9. Overactive Bladder Preclinical Stage Products
10. Overactive Bladder Therapeutics Assessment
11. Overactive Bladder Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Overactive Bladder Key Companies
14. Overactive Bladder Key Products
15. Overactive Bladder Unmet Needs
16 . Overactive Bladder Market Drivers and Barriers
17. Overactive Bladder Future Perspectives and Conclusion
18. Overactive Bladder Analyst Views
19. Appendix
20. About DelveInsight
Related Reports:
Overactive Bladder Market https://www.delveinsight.com/report-store/overactive-bladder-oab-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Overactive Bladder Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Overactive Bladder Epidemiology https://www.delveinsight.com/report-store/overactive-bladder-oab-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Overactive Bladder Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports:
H3n2 Infection Market
https://www.delveinsight.com/report-store/h3n2-infection-market
DelveInsight's "H3N2 Infection Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the H3N2 Infection, historical and forecasted epidemiology as well as the H3N2 Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Herpes Simplex Virus Market
https://www.delveinsight.com/report-store/herpes-simplex-market
DelveInsight's "Herpes Simplex Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Herpes Simplex, historical and forecasted epidemiology as well as the Herpes Simplex market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Hypercoagulability Market
https://www.delveinsight.com/report-store/hypercoagulability-market
DelveInsight's "Hypercoagulability Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hypercoagulability, historical and forecasted epidemiology as well as the Hypercoagulability market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Liver Angiosarcoma Market
https://www.delveinsight.com/report-store/liver-angiosarcoma-market
DelveInsight's "Liver Angiosarcoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Liver Angiosarcoma, historical and forecasted epidemiology as well as the Liver Angiosarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Point Of Care Glucose Testing Market
https://www.delveinsight.com/report-store/point-of-care-glucose-testing-market
DelveInsight's 'Point of Care Glucose Testing Market Insight, Competitive Landscape and Market Forecast, 2030' report delivers an in-depth understanding of Point of Care Glucose Testing and the historical and forecasted Point of Care Glucose Testing market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Resorbable Vascular Scaffold Market
https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market
DelveInsight's 'Resorbable Vascular Scaffolds - Market Insight, Competitive Landscape, and Market Forecast - 2030' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage
to this press release on woodPRI. woodPRI disclaims liability for any content contained in
this release.
Recommend
/newsMicroencapsulation Market Deep Analysis on Key Players - Dow Corning, Encapsys, Syngenta Crop Protection, Evonik Industries, 3M and Bayer
Market Study Report Adds Global Microencapsulation Market Size, Status and Forecast 2024 added to its database. The report provides key statistics on the current state of the industry and other analytical data to understand the market.
Extensive research is required for choosing the appropriate cor...
/newsGermany Airbag Market Size 2023: Global Share, Industry And Report Analysis By 2030 | Hyundai Mobis Co., Ltd. Key Safety Systems, Inc. Robert Bosch GmbH
Germany airbag market is expected to grow at a CAGR of around 6% during the forecast period. Germany Airbag Market research report refers to gathering and analyzing significant market data serve as best medium for various industry players to launch novel product or service. It is vital for key firms...
/newsSecurities Brokerages And Stock Exchanges Market Outlook 2021: Big Things are Happening
A new intelligence report released by HTF MI with title "Global Securities Brokerages And Stock Exchanges Market Survey & Outlook" is designed covering micro level of analysis by Insurers and key business segments, offerings and sales channels. The Global Securities Brokerages And Stock Exchange...
/newsRenewable Chemicals Market Emerging Trends and Competitive Landscape Forecast to 2028
The renewable chemicals market was valued at US$ 80,566.30 million in 2021 and is projected to reach US$ 1,76,750.76 million by 2028 it is expected to grow at a CAGR of 11.9% from 2021 to 2028. The research report focuses on the current market trends, opportunities, future potential of the market, a...
/newsHow Coronavirus is Impacting Cold Brew Coffee, Global Market Volume Analysis, Size, Share and Key Trends 2020-2026
"Market Latest Research Report 2020:
Los Angles United States, February 2020: The Cold Brew Coffee market has been garnering remarkable momentum in the recent years. The steadily escalating demand due to improving purchasing power is projected to bode well for the global market. QY Research's lates...
/newsCorporate E-Learning Market - Global Industry Size, Share, Key Players Analysis that are Infor, SkillSoft Corporation, Adrenna, CERTPOINT Systems and others with Regional Forecast to 2022
Overview:
E-Learning is used to enhance the learning procedures for newer job requirements and to make employees sound about the internal and external changes in the market and respective organizations. This method has created considerable differences in the ways of training and developing employee...
